<DOC>
	<DOCNO>NCT02138136</DOCNO>
	<brief_summary>A study long-term safety efficacy Lubiprostone subject age ≥ 6 &lt; 18 year diagnose Functional Constipation</brief_summary>
	<brief_title>Long-term Safety Efficacy Lubiprostone Subjects Aged ≥ 6 Years &lt; 18 Years With Functional Constipation</brief_title>
	<detailed_description>The purpose study ass long-term safety , efficacy , pharmacokinetics oral lubiprostone 12 24 mcg capsule dose twice daily ( BID ) administer orally 36 week paediatric subject functional constipation .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Completed 12 week blind treatment SAG/0211PFC1131 study . Continue abstain take concomitant medication ( prescribed overthecounter ) affect gastrointestinal motility . Untreated faecal impaction time roll study . Significant change medical status , newly diagnose uncontrolled cardiovascular , liver lung disease , neurologic psychiatric disorder , systemic disease . Demonstrated noncompliance study protocol SAG/0211PFC1131 study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>